United Therapeutics Corp (NAS:UTHR)
$ 264.27 -1.78 (-0.67%) Market Cap: 11.72 Bil Enterprise Value: 9.69 Bil PE Ratio: 12.50 PB Ratio: 2.19 GF Score: 89/100

United Therapeutics Corp at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 09, 2020 / 07:45PM GMT
Release Date Price: $136.26 (+0.28%)
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Okay, everybody. This is Marty Auster. I'm the lead SMID biotech analyst here at Crédit Suisse. You are joining me today to discuss United Therapeutics at the 29th Annual Crédit Suisse Health Care Conference. I think this is the first time I've had the pleasure of hosting my friends from United Therapeutics at the Health Care Conference.

I've got Mike Benkowitz, the Chief Operating Officer and President of United Therapeutics. And I'm going to pass it over to Dewey Steadman, Head of Investor Relations, to make a few forward-looking statements, and then we'll kind of kickoff some Q&A. Dewey?

Dewey Steadman
United Therapeutics Corporation - Head of IR

Yes. Good Afternoon. Our remarks today may include forward-looking information about our business. Please see our SEC filings for risks and uncertainties that could cause actual results to differ. And thank you. So I'll turn it back over to you, Marty.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot